

Author index

Volume 63 (2004)

- Andronova, V., see Skoblov, Y. **63**, 107
- Asmuth, D.M., M.P. Busch, M.E. Laycock, B.A. Mohr, L.A. Kalish, C.M. van der Horst, Hepatitis B and C viral load changes following initiation of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection **63**, 123
- Asper, M., see Günther, S. **63**, 209
- Bakker, H.I., see Beljaars, L. **63**, 197
- Balzarini, J., see Rao, A. **63**, 79
- Barr, I.G., see Cheam, A.L. **63**, 177
- Becker-Ziaja, B., see Günther, S. **63**, 209
- Beljaars, L., B.W.A. van der Strate, H.I. Bakker, C. Reker-Smit, A.-m. van Loenen-Weemaes, F.C. Wiegman, M.C. Harmsen, G. Molema, D.K.F. Meijer, Inhibition of cytomegalovirus infection by lactoferrin in vitro and in vivo **63**, 197
- Bergström, T., see Nyberg, K. **63**, 15
- Betts, R.F., see Eun-Hyung Lee, F. **63**, 191
- Bidanset, D.J., R.J. Rybak, C.B. Hartline, E.R. Kern, Efficacy of ganciclovir and cidofovir against human cytomegalovirus replication in SCID mice implanted with human retinal tissue **63**, 61
- Bischofberger, N., see Van Rompay, K.K.A. **63**, 133
- Blatt, L.M., see Morrey, J.D. **63**, 41
- Borowski, P., see Günther, S. **63**, 209
- Bowlin, T.L., see Wyde, P.R. **63**, 51
- Busch, M.P., see Asmuth, D.M. **63**, 123
- Carbone, A., see Rao, A. **63**, 79
- Cebula, T.A., see Goswami, B.B. **63**, 153
- Chang, W.-Y., see Yu, M.-L. **63**, 25
- Charlier, N., P. Leyssen, E. De Clercq, J. Neyts, Rodent models for the study of therapy against flavivirus infections **63**, 67
- Cheam, A.L., I.G. Barr, A.W. Hampson, J. Mosse, A.C. Hurt, In vitro generation and characterisation of an influenza B variant with reduced sensitivity to neuraminidase inhibitors **63**, 177
- Chen, H.-M., see Günther, S. **63**, 209
- Chen, H.-Y., see Jiang, S.-J. **63**, 167
- Chen, S.-C., see Yu, M.-L. **63**, 25
- Cheney, C.D., see Morrey, J.D. **63**, 41
- Chetty, S.N., see Wyde, P.R. **63**, 51
- Chimiri, A., see Rao, A. **63**, 79
- Chong, Y., C.K. Chu, Molecular mechanism of dioxolane nucleosides against 3TC resistant M184V mutant HIV **63**, 7
- Chu, C.K., see Chong, Y. **63**, 7
- Chuang, W.-L., see Yu, M.-L. **63**, 25
- Collins, D.J., see Quenelle, D.C. **63**, 33
- Cote, P.J., see Jacob, J.R. **63**, 115
- Dai, C.-Y., see Yu, M.-L. **63**, 25
- Day, C.W., see Morrey, J.D. **63**, 41
- de Bie, P., see Georgiou, N.A. **63**, 97
- De Clercq, E., see Charlier, N. **63**, 67
- De Clercq, E., see Rao, A. **63**, 79
- Delaney IV, W.E., see Jacob, J.R. **63**, 115
- Drosten, C., see Günther, S. **63**, 209
- Ekblad, M., see Nyberg, K. **63**, 15
- Eng, H.-L., see Jiang, S.-J. **63**, 167
- Eun-Hyung Lee, F., E.E. Walsh, A.R. Falsey, R.F. Betts, J.J. Treanor, Experimental infection of humans with A2 respiratory syncytial virus **63**, 191
- Evers, D.L., X. Wang, S.-M. Huong, D.Y. Huang, E.-S. Huang, 3,4',5-Trihydroxy-*trans*-stilbene (resveratrol) inhibits human cytomegalovirus replication and virus-induced cellular signaling **63**, 85
- Falsey, A.R., see Eun-Hyung Lee, F. **63**, 191
- Ferro, V., see Nyberg, K. **63**, 15
- Freeman, C., see Nyberg, K. **63**, 15
- Galegov, G., see Skoblov, Y. **63**, 107
- Georgiou, N.A., T. van der Bruggen, M. Oudshoorn, P. de Bie, C.A. Jansen, H.S.L.M. Nottet, J.J.M. Marx, B.S. van Asbeck, Mechanism of inhibition of the human immunodeficiency virus type 1 by the oxygen radical generating agent bleomycin **63**, 97
- Gerin, J.L., see Jacob, J.R. **63**, 115
- Goswami, B.B., M. Kulka, D. Ngo, T.A. Cebula, Apoptosis induced by a cytopathic hepatitis A virus is dependent on caspase activation following ribosomal RNA degradation but occurs in the absence of 2'-5' oligoadenylate synthetase **63**, 153
- Günther, S., M. Asper, C. Röser, L.K.S. Luna, C. Drosten, B. Becker-Ziaja, P. Borowski, H.-M. Chen, R.S. Hosmane, Application of real-time PCR for testing antiviral compounds against Lassa virus, SARS coronavirus and Ebola virus in vitro **63**, 209
- Hampson, A.W., see Cheam, A.L. **63**, 177
- Harmsen, M.C., see Beljaars, L. **63**, 197
- Harrington, P., see Taggart, B.R. **63**, 1
- Hartline, C.B., see Bidanset, D.J. **63**, 61
- He, K., see Liu, F. **63**, 183
- Hollingshead, M., see Taggart, B.R. **63**, 1
- Hosmane, R.S., see Günther, S. **63**, 209
- Hsieh, M.-Y., see Yu, M.-L. **63**, 25
- Huang, D.Y., see Evers, D.L. **63**, 85
- Huang, E.-S., see Evers, D.L. **63**, 85
- Huang, J.-F., see Yu, M.-L. **63**, 25
- Huong, S.-M., see Evers, D.L. **63**, 85
- Hurt, A.C., see Cheam, A.L. **63**, 177
- Jacob, J.R., B.E. Korba, P.J. Cote, I. Toshkov, W.E. Delaney IV, J.L. Gerin, B.C. Tennant, Suppression of lamivudine-resistant B-domain mutants by adefovir dipivoxil in the woodchuck hepatitis virus model **63**, 115
- Jansen, C.A., see Georgiou, N.A. **63**, 97
- Jewell, A., see Wyde, P.R. **63**, 51

- Jiang, S.-J., T.-M. Lin, G.-Y. Shi, H.-L. Eng, H.-Y. Chen, H.-L. Wu, Inhibition of bovine herpesvirus-4 replication in endothelial cells by arsenite **63**, 167
- Julander, J.G., see Morrey, J.D. **63**, 41
- Kalish, L.A., see Asmuth, D.M. **63**, 123
- Karpenko, I., see Skoblov, Y. **63**, 107
- Kern, E.R., see Bidanset, D.J. **63**, 61
- Kern, E.R., see Quenelle, D.C. **63**, 33
- Kimberlin, D.W., Current status of antiviral therapy for juvenile-onset recurrent respiratory papillomatosis **63**, 141
- Korba, B.E., see Jacob, J.R. **63**, 115
- Kukhanova, M., see Skoblov, Y. **63**, 107
- Kulka, M., see Goswami, B.B. **63**, 153
- Laycock, M.E., see Asmuth, D.M. **63**, 123
- Lee, L.-P., see Yu, M.-L. **63**, 25
- Leyssen, P., see Charlier, N. **63**, 67
- Lin, T.-M., see Jiang, S.-J. **63**, 167
- Lin, Z.-Y., see Yu, M.-L. **63**, 25
- Liu, F., Y. Liu, Y. Meng, M. Yang, K. He, Structure of polysaccharide from *Polygonatum cyrtoneura* Hua and the antiherpetic activity of its hydrolyzed fragments **63**, 183
- Liu, Y., see Liu, F. **63**, 183
- Luna, L.K.S., see Günther, S. **63**, 209
- Marthas, M.L., see Van Rompay, K.K.A. **63**, 133
- Marx, J.J.M., see Georgiou, N.A. **63**, 97
- Meijer, D.K.F., see Beljaars, L. **63**, 197
- Meng, Y., see Liu, F. **63**, 183
- Mohr, B.A., see Asmuth, D.M. **63**, 123
- Molema, G., see Beljaars, L. **63**, 197
- Monforte, A.M., see Rao, A. **63**, 79
- Monforte, P., see Rao, A. **63**, 79
- Morrey, J.D., C.W. Day, J.G. Julander, A.L. Olsen, R.W. Sidwell, C.D. Cheney, L.M. Blatt, Modeling hamsters for evaluating West Nile virus therapies **63**, 41
- Mosse, J., see Cheam, A.L. **63**, 177
- Moylett, E.H., see Wyde, P.R. **63**, 51
- Neyts, J., see Charlier, N. **63**, 67
- Ngo, D., see Goswami, B.B. **63**, 153
- Nottet, H.S.L.M., see Georgiou, N.A. **63**, 97
- Nyberg, K., M. Ekblad, T. Bergström, C. Freeman, C.R. Parish, V. Ferro, E. Trybala, The low molecular weight heparan sulfate-mimetic, PI-88, inhibits cell-to-cell spread of herpes simplex virus **63**, 15
- Olsen, A.L., see Morrey, J.D. **63**, 41
- Oudshoorn, M., see Georgiou, N.A. **63**, 97
- Pannecouque, C., see Rao, A. **63**, 79
- Parish, C.R., see Nyberg, K. **63**, 15
- Piedra, P.A., see Wyde, P.R. **63**, 51
- Popov, K., see Skoblov, Y. **63**, 107
- Quenelle, D.C., D.J. Collins, E.R. Kern, Cutaneous infections of mice with vaccinia or cowpox viruses and efficacy of cidofovir **63**, 33
- Rao, A., J. Balzarini, A. Carbone, A. Chimirri, E. De Clercq, A.M. Monforte, P. Monforte, C. Pannecouque, M. Zappalà, 2-(2,6-Dihalophenyl)-3-(pyrimidin-2-yl)-1,3-thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors **63**, 79
- Reker-Smit, C., see Beljaars, L. **63**, 197
- Röser, C., see Günther, S. **63**, 209
- Rybak, R.J., see Bidanset, D.J. **63**, 61
- Shi, G.-Y., see Jiang, S.-J. **63**, 167
- Shirokova, E., see Skoblov, Y. **63**, 107
- Sidwell, R.W., see Morrey, J.D. **63**, 41
- Skoblov, Y., I. Karpenko, E. Shirokova, K. Popov, V. Andronova, G. Galegov, M. Kukhanova, Intracellular metabolism and pharmacokinetics of 5'-hydrogenphosphonate of 3'-azido-2',3'-dideoxythymidine, a pro-drug of 3'-azido-2',3'-dideoxythymidine **63**, 107
- Taggart, B.R., P. Harrington, M. Hollingshead, HIV hollow fiber SCID model for antiviral therapy comparison with SCID/hu model **63**, 1
- Tennant, B.C., see Jacob, J.R. **63**, 115
- Toshkov, I., see Jacob, J.R. **63**, 115
- Treanor, J.J., see Eun-Hyung Lee, F. **63**, 191
- Trybala, E., see Nyberg, K. **63**, 15
- van Asbeck, B.S., see Georgiou, N.A. **63**, 97
- van der Bruggen, T., see Georgiou, N.A. **63**, 97
- van der Horst, C.M., see Asmuth, D.M. **63**, 123
- van der Strate, B.W.A., see Beljaars, L. **63**, 197
- van Loenen-Weemaes, A.-m., see Beljaars, L. **63**, 197
- Van Rompay, K.K.A., M.L. Marthas, N. Bischofberger, Tenofovir primes rhesus macaque cells in vitro for enhanced interleukin-12 secretion **63**, 133
- Walsh, E.E., see Eun-Hyung Lee, F. **63**, 191
- Wang, L.-Y., see Yu, M.-L. **63**, 25
- Wang, X., see Evers, D.L. **63**, 85
- Wiegman, F.C., see Beljaars, L. **63**, 197
- Wu, H.-L., see Jiang, S.-J. **63**, 167
- Wyde, P.R., E.H. Moylett, S.N. Chetty, A. Jewell, T.L. Bowlin, P.A. Piedra, Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by NMSO3 in tissue culture assays **63**, 51
- Yang, M., see Liu, F. **63**, 183
- Yu, M.-L., C.-Y. Dai, S.-C. Chen, L.-P. Lee, J.-F. Huang, Z.-Y. Lin, M.-Y. Hsieh, L.-Y. Wang, W.-L. Chuang, W.-Y. Chang, A prospective study on treatment of chronic hepatitis C with tailored and extended interferon-alpha regimens according to pretreatment virological factors **63**, 25
- Zappalà, M., see Rao, A. **63**, 79